TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02697552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Description: Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
Study: NCT01494766

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L-Tyrosine
Description: L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
Study: NCT00927966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once a day.
Study: NCT00625638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
Study: NCT01643889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (domperidone 20 mg)
Description: 2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (domperidone 20 mg)
Description: 2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (domperidone 20 mg)
Description: 2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Study: NCT00927966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Given intravenously on Day 1 of a 21-day cycle
Study: NCT01643889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (placebo)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (placebo)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (placebo)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (placebo)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D (moxifloxacin)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D (moxifloxacin)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D (moxifloxacin)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D (moxifloxacin)
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
Study: NCT02591056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Verju™ Laser
Description: There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green PRESS 8
Description: There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
Study: NCT03676088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root coverage
Description: recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage
Description: recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
Study: NCT05325983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lemonade ice cubes
Description: Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water ice cubes
Description: make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
Study: NCT03792178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk fill composite
Description: Composite resin dental material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill composite
Description: Composite resin dental material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano resin composite
Description: Dental composite material
Study: NCT00792324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine
Description: Four 100mg tablets daily for 12-24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: One 600mg tablet daily
Study: NCT01922336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB2
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU Remicade
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Remicade
Description: IV infusion
Study: NCT01373294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerrin (BCG)
Description: Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacille Calmette-Guerrin (BCG)
Description: Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
Study: NCT02912793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Used in the treatment of Niemann-Pick C1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Used in the treatment of Niemann-Pick C1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Used in the treatment of Niemann-Pick C1
Study: NCT02348931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of customized nasal brace (Nasella) for nose deformities

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of customized nasal brace (Nasella) for nose deformities

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corrective surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corrective surgery
Study: NCT00078715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Description: Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Description: Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
Study: NCT03108989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
Study: NCT04171752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: elafibranor 120mg is a coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: elafibranor 120mg is a coated tablet for oral administration
Study: NCT00413231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft System
Description: Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
Study: NCT05713331

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLS-R
Description: CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-R
Description: CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
Study: NCT03040479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: single dose
Study: NCT00775931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine monophosphate
Description: Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: marrow graft transplantation
Description: Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
Study: NCT03893019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
Study: NCT02029196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-vapour product
Description: Smokers of conventional cigarettes who switch to use an e-vapour product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette
Description: Smokers of conventional cigarettes who continue smoking conventional cigarettes.
Study: NCT01302535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga group with supervision (trainer)
Description: The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga at home
Description: The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
Study: NCT02178215

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo shower gel
Description: Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holly Mangrove Shower Gel
Description: Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
Study: NCT00808132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
Study: NCT00031564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7-1
Study: NCT05804149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Thyroxine
Description: Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
Study: NCT02568605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fibre
Description: Oligofructose-enriched inulin (Synergy1)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT05804149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low caloric diet
Description: Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
Study: NCT02568605

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Loss
Description: All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
Study: NCT01947998

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, Bay59-7939)
Description: The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).

Intervention type: DRUG
Intervention: Warfarin
Description: For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.

Intervention type: DRUG
Intervention: Antiplatelet drugs
Description: For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
Study: NCT02590965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
Study: NCT00808132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene 20 mg
Description: One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
Study: NCT02590965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
Study: NCT03247179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTSD Coach mobile application
Description: The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
Study: NCT00288730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study: NCT04316793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
Study: NCT00808132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
Description: One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
Study: NCT05804149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
Study: NCT00808132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, placebo (over-encapsulated), once a day for one year.
Study: NCT01494727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Amlodipine/Valsartan 10/160mg
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Exforge 10/160mg
Description: single dose
Study: NCT01743066

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: vitamin E (200 IU, caplet) daily orally for 20 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: vitamin E (200 IU, caplet) daily orally for 20 weeks